Fig. 2 | Nature Communications

Fig. 2

From: Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA

Fig. 2

Cardiac cfDNA in healthy subjects and in patients with myocardial infarction. a Cardiac cfDNA (copies of fully unmethylated FAM101A /ml plasma) in samples from healthy controls (Ctrls, n = 83) and patients during STEMI (MI, n = 74 samples from 31 patients). Mann–Whitney test for controls vs. patients, p-value < 0.0001. b Receiver operating characteristic (ROC) curve for the diagnosis of STEMI by demethylated FAM101A in plasma of healthy controls and patients with MI. Area under the curve (AUC) 0.94 (95% CI = 0.9044 to 0.983), p-value < 0.0001. c Comparison of unmethylated FAM101A levels (copies/ml) in healthy controls, STEMI samples with normal Creatine Kinase (CPK < 200) and STEMI samples with high CPK (CK > 200). Kruskal-Wallis test p-value < 0.0001. Dunn’s multiple comparisons test: Controls (Ctrls) vs. STEMI with normal CPK, p-value < 0.001; Ctrls vs. STEMI with high CPK, p-value < 0.0007; STEMI with normal CPK vs. STEMI with high CPK, p-value = 0.0068. d Comparison of unmethylated FAM101A levels in healthy controls, samples from STEMI patients with normal levels of high-sensitive cardiac troponin T (hs-cTn) (<0.03), and samples from STEMI patients with high levels of hs-cTn (>0.03). Kruskal–Wallis test p-value < 0.0001. Dunn’s multiple comparisons test: Ctrls vs. STEMI with normal hs-cTn, p-value = 0.6863; Ctrls vs. STEMI with high hs-cTn, p-value < 0.0001; STEMI with normal hs-cTn vs. STEMI with high hs-cTn (>0.03), p-value = 0.0307. e Spearman correlation between cardiac cfDNA and troponin levels in 57 STEMI patients. Curved line, non linear (quadratic) fit. f XY Scatter plot for cardiac cfDNA levels vs. cardiac troponin. Quadrants indicate negative and positive hs-cTn, and negative and positive cardiac cfDNA. Numbers indicate the percentage of samples in each quadrant

Back to article page